-
Product Insights
NewAchiko AG Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Achiko AG Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Achiko AG (Achiko) designs and develops software solutions. The Company offers an API platform for developers, mobile payment services, e-sports, and products for COVID-19 test results management and contact tracing. It is headquartered in Zurich, Switzerland. GlobalData's Medical Devices company profile report, “Achiko AG Pipeline Insight and Competitive Landscape, 2023" provides information about the company overview and analysis on their...
-
Product Insights
NewSynDermix AG Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our SynDermix AG Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. SynDermix AG (SynDermix), formerly Pharmagenix AG, is a clinical-stage biotechnology company which develops bio-pharmaceutical products and medical devices for treating rare diseases, chronic wounds and ENT (ears, nose and throat) disorders. Its product portfolio includes SDX-3101 for treating chronic rhinosinusitis, SDX-3103 against migraine, SDX-3104 indicated for chronic wounds. The company's vibration therapies are based on connected medical devices that provide...
-
Product Insights
NewNet Present Value Model: CRISPR Therapeutics AG’s CTX-130
Empower your strategies with our Net Present Value Model: CRISPR Therapeutics AG's CTX-130 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: CRISPR Therapeutics AG’s CTX-120
Empower your strategies with our Net Present Value Model: CRISPR Therapeutics AG's CTX-120 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Sandoz Group AG’s Aflibercept Biosimilar
Empower your strategies with our Net Present Value Model: Sandoz Group AG's Aflibercept Biosimilar report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: CRISPR Therapeutics AG’s CTX-131
Empower your strategies with our Net Present Value Model: CRISPR Therapeutics AG's CTX-131 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: CRISPR Therapeutics AG’s CTX-110
Empower your strategies with our Net Present Value Model: CRISPR Therapeutics AG's CTX-110 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Oculis Holding AG’s Dexamethasone Acetate
Empower your strategies with our Net Present Value Model: Oculis Holding AG's Dexamethasone Acetate report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Innovation Ranking
Innovation Ranking – HeidelbergCement AG
HeidelbergCement AG (HeidelbergCement) is a provider of building materials. The company carries out the production and distribution of cement and aggregates including gravel, sand, and crushed rock. It also produces ready-mixed concrete, asphalt, and other building materials such as gypsum and limestone; and carries out the trading of cement, solid fuels, clinker, and other building materials by sea. It trades cement and coal by sea across the globe. HeidelbergCement serves the construction of infrastructure, houses and commercial and industrial facilities....
-
Innovation Ranking
Innovation Ranking – Novartis AG
Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company...